Benign breast tissue sampling for prevention studies

Breast Journal

Volumn 6, Issue 4, 2000, Pages 215-219

  Fabian, Carol ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; ESTRADIOL; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN; TESTOSTERONE;

ASPIRATION BIOPSY; BREAST BIOPSY; BREAST CANCER; BREAST EPITHELIUM; CANCER INCIDENCE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DISEASE MARKER; EDITORIAL; FEMALE; HUMAN; MAMMOGRAPHY; STEREOTAXIC SURGERY;

EID: 0033860888     PISSN: 1075122X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1524-4741.2000.20024.x     Document Type: Editorial

References (67)

1. Yield of terminal ductal lobule units (TDLU) in normal breast stereotactic core biopsy specimens: Implications of biomarker studies
2. Projected probabilities of developing breast cancer for white females who are being examined annually
3. Validation studies for models projecting the risk of invasive and total breast cancer incidence
4. Development of breast cancer chemopreventive drugs
5. Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women
6. Tamoxifen for prevention of breast cancer. Report of the National Surgical Adjuvant Breast and Bowel Project P-1 study
7. New perspective on cancer of the contralateral breast: A marker for assessing tamoxifen as a prevention agent [editorial]
8. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group
9. Can fenretinide protect women against ovarian cancer?
10. Breast cancer chemoprevention with retinoids and tamoxifen
11. The effect of raloxifene on risk of breast cancer in postmenopausal women: Results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation
12. Fostering chemopreventive agent development: How to proceed?
13. Phase III, large-scale chemoprevention trials
14. Mechanistic considerations in chemopreventive drug development
15. Progress in cancer chemoprevention: Perspectives on agent selection and short-term clinical intervention trials
16. Intraepithelial neoplasia, surrogate endpoint biomarkers, and cancer chemoprevention
17. Biomarkers of premalignant breast disease and their use as surrogate endpoints in clinical trials of chemopreventive agents
18. Statistical validation of intermediate markers of precancer for use as endpoints in chemoprevention trials
19. The clinical evaluation of cancer chemoprevention agents: Defining and contrasting phase I, II, and III objectives
20. Risk biomarkers and current strategies for cancer chemoprevention
21. Mammographic features and breast cancer risk: Effects with time, age and menopausal status
22. Mammographic densities and breast cancer risk
23. Mammographic densities and risk of breast cancer among subjects with a family history of this disease
24. Genetic analysis of mammographic breast density in adult women: Evidence of a gene effect
25. Macronutrient intake and change in mammographic density at menopause: Results from a randomized trial
26. Effect of tamoxifen on serum insulin-like growth factor I levels in stage I breast cancer patients
27. Insulin-like growth factor-1: A key regulator of human risk?
28. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer
29. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients
30. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer
31. Surrogate end points in cancer research: A critique [editorial]
32. Lobular neoplasia of the breast: Higher risk for subsequent invasive cancer by more extensive disease
33. Atypical hyperplastic lesions of the female breast. A long-term follow-up study
34. Anatomic markers of human premalignancy and risk of breast cancer
35. A comparison of the results of long-term followup for atypical intraductal hyperplasia and intraductal hyperplasia of the breast
36. Morphofunctional features of intraductal hyperplasia, atypical intraductal hyperplasia, and various grades of intraductal carcinoma
37. Breast cancer following benign breast disease - A nationwide study
38. Risk of breast cancer associated with atypical hyperplasia of lobular and ductal types
39. Prospective evaluation of radiologically directed fine-needle aspiration biopsy of nonpalpable breast lesions
40. Image cytometric classification of premalignant breast disease in fine needle aspirates
41. Quantitation of preinvasive neoplastic progression in animal models of chemical carcinogenesis
42. The incidence of microsatellite instability and loss of heterozygosity in fibroadenoma of the breast
43. Loss of heterozygosity at 3p in benign lesions preceding invasive breast cancer
44. Development of new cancer chemoprevention agents: Role of pharmacokinetic/pharmacodynamic and intermediate endpoint biomarker monitoring
45. Searching for evidence of altered gene expression: A comment on statistical analysis of microarray data
46. Alterations in DNA methylation: A fundamental aspect of neoplasia
47. E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas
48. Methylation of the estrogen receptor gene CpG island marks loss of estrogen receptor expression in human breast cancer cells
49. Premalignant breast lesions: Role for biological markers in predicting progression to cancer
50. Biomarkers in benign breast disease: Risk factors for breast cancer
51. A plea for standardization of biomarker assays in the study of high risk, premalignant and malignant breast disease [editorial]
52. Final version: The uniform approach to breast fine-needle aspiration biopsy
53. Prognostic biomarkers in breast cancer: Factors affecting immunohistochemical evaluation
54. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia
55. Effect of fixation and tissue processing on immunohistochemical demonstration on specific antigens
56. Surrogate end points in clinical trials: Are we being misled?
57. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions
58. Hormonal chemoprevention of cancer in women
59. Models for early chemoprevention trials in breast cancer
60. Breast cancer risk associated with abnormal cytology in nipple aspirates of breast fluid and prior history of breast biopsy
61. Nipple aspirate fluid: A promising non-invasive method to identify cellular markers of breast cancer risk
62. Detection of proliferative breast disease by four-quadrant, fine needle aspiration
63. Cytologic identification of clinically occult proliferative breast disease in women with a family history of breast cancer
64. Random fine needle aspiration of the breast of women at increased breast cancer risk and standard risk controls
65. Potential use of biomarkers in breast cancer risk assessment and chemoprevention trials
66. Breast cytology and biomarkers obtained by random fine needle aspiration: Use in risk assessment and early chemoprevention trials
67. Specimen mammography-guided fine-needle aspirates of mammographically normal fatty and dense benign tissue: Analysis of cell number and type